Published in Breast Cancer Res on March 10, 2015
Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients. J Immunother Cancer (2015) 0.82
Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer. J Transl Med (2016) 0.77
Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty. Breast Cancer Res (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity (2009) 9.01
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol (2007) 6.68
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 6.23
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol (2004) 3.50
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother (2010) 3.00
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother (2011) 2.97
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res (2010) 2.74
Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res (2005) 2.32
Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res (2012) 2.25
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A (1995) 1.71
The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine (2012) 1.54
Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest (2012) 1.43
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res (2013) 1.43
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother (2013) 1.42
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res (2009) 1.38
Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res (2013) 1.34
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother (2007) 1.32
Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother (2010) 1.12
Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer. Int J Cancer (2012) 0.96
Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep (2013) 0.94
Immunosenescence and cancer. Crit Rev Oncog (2013) 0.90
Modulation of CD8(+) T-cell activation events by monocytic and granulocytic myeloid-derived suppressor cells. Immunobiology (2013) 0.86
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy (2014) 0.83
Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). Oncol Rep (2014) 0.82
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Epigenetic and immune function profiles associated with posttraumatic stress disorder. Proc Natl Acad Sci U S A (2010) 2.85
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Cytomegalovirus and human immunosenescence. Rev Med Virol (2009) 2.31
An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci (2005) 2.15
Age-associated accumulation of CMV-specific CD8+ T cells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1). Exp Gerontol (2003) 2.11
Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda) (2008) 2.09
Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One (2011) 2.08
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Aging and innate immunity. Immunity (2006) 1.95
Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J Clin Immunol (2003) 1.94
Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci (2007) 1.87
The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech Ageing Dev (2006) 1.85
Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res (2009) 1.75
Is human aging still mysterious enough to be left only to scientists? Bioessays (2002) 1.59
Immunosenescence and vaccination in nursing home residents. Clin Infect Dis (2009) 1.57
Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing (2008) 1.57
Dysfunctional CMV-specific CD8(+) T cells accumulate in the elderly. Exp Gerontol (2004) 1.55
The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine (2012) 1.54
Human cytomegalovirus infection and T cell immunosenescence: a mini review. Mech Ageing Dev (2006) 1.53
No Immune Risk Profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study. Exp Gerontol (2007) 1.51
Biomarkers of human immunosenescence: impact of Cytomegalovirus infection. Curr Opin Immunol (2009) 1.51
Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother (2009) 1.44
Hallmark features of immunosenescence are absent in familial longevity. J Immunol (2010) 1.43
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res (2013) 1.43
Multi-parametric phospho-flow cytometry: a crucial tool for T lymphocyte signaling studies. Cytometry A (2013) 1.41
Role of CMV in immune senescence. Virus Res (2010) 1.35
The genetics of human longevity. Ann N Y Acad Sci (2006) 1.30
Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. J Gen Virol (2011) 1.29
The impact of CMV infection on survival in older humans. Curr Opin Immunol (2012) 1.28
Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer (2009) 1.24
Dysregulation of T-cell function in the elderly : scientific basis and clinical implications. Drugs Aging (2005) 1.23
Immunosenescence and Cytomegalovirus: where do we stand after a decade? Immun Ageing (2010) 1.22
Role of persistent CMV infection in configuring T cell immunity in the elderly. Immun Ageing (2007) 1.21
Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. Biogerontology (2006) 1.20
Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis (2009) 1.20
Report from the second cytomegalovirus and immunosenescence workshop. Immun Ageing (2011) 1.19
Mechanisms of immunosenescence. Immun Ageing (2009) 1.19
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res (2009) 1.19
CMV and Immunosenescence: from basics to clinics. Immun Ageing (2012) 1.17
Gene expression analysis of mTOR pathway: association with human longevity. Aging Cell (2012) 1.17
An age-related increase in the number of CD8+ T cells carrying receptors for an immunodominant Epstein-Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech Ageing Dev (2003) 1.17
Immunity, ageing and cancer. Immun Ageing (2008) 1.13
Aging, immunity, and cancer. Discov Med (2011) 1.11
Oxidative stress modulation and T cell activation. Exp Gerontol (2007) 1.10
Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine (2012) 1.10
Potential role of immunosenescence in cancer development. Ann N Y Acad Sci (2010) 1.10
High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer (2010) 1.07
Impact of age on T cell signaling: a general defect or specific alterations? Ageing Res Rev (2010) 1.07
Lower proportion of naïve peripheral CD8+ T cells and an unopposed pro-inflammatory response to human Cytomegalovirus proteins in vitro are associated with longer survival in very elderly people. Age (Dordr) (2012) 1.06
Ageing, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing - a biochemical paradigm for the ageing immune system. Arthritis Res Ther (2003) 1.05
Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res (2011) 1.04
OMIP-020: phenotypic characterization of human γδ T-cells by multicolor flow cytometry. Cytometry A (2014) 1.01
Immunosenescence and cancer. Crit Rev Oncol Hematol (2010) 1.00
Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma. Cancer Immunol Immunother (2010) 1.00
Immune receptor signaling, aging and autoimmunity. Adv Exp Med Biol (2008) 1.00
Impact of CMV and EBV seropositivity on CD8 T lymphocytes in an old population from West-Sicily. Exp Gerontol (2007) 0.99
High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. Eur J Immunol (2005) 0.98
From bench to bedside and back: the SENIEUR Protocol and the efficacy of influenza vaccination in the elderly. Biogerontology (2008) 0.98
Immunosupportive therapies in aging. Clin Interv Aging (2007) 0.97
Immune profiling of Alzheimer patients. J Neuroimmunol (2011) 0.94
NKp80 defines and stimulates a reactive subset of CD8 T cells. Blood (2008) 0.93
Rudimentary signs of immunosenescence in Cytomegalovirus-seropositive healthy young adults. Age (Dordr) (2013) 0.93
Gene expression changes in long-term culture of T-cell clones: genomic effects of chronic antigenic stress in aging and immunosenescence. Aging Cell (2007) 0.92
Age and immunity. Immun Ageing (2006) 0.91
The European searchable tumour line database. Cancer Immunol Immunother (2009) 0.91
Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands. Cancer Immunol Immunother (2006) 0.91
Age related microsatellite instability in T cells from healthy individuals. Exp Gerontol (2004) 0.91
Compromised interferon gamma (IFN-gamma) production in the elderly to both acute and latent viral antigen stimulation: contribution to the immune risk phenotype? Eur Cytokine Netw (2003) 0.90
Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother (2009) 0.90
Induction of HIF-1alpha and the glycolytic pathway alters apoptotic and differentiation profiles of activated human T cells. J Leukoc Biol (2009) 0.89
HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones. Cancer Immunol Immunother (2001) 0.89
Cytomegalovirus seropositivity is associated with glucose regulation in the oldest old. Results from the Leiden 85-plus Study. Immun Ageing (2012) 0.89
HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. Cancer Immunol Immunother (2007) 0.89
Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy. Cancer Immunol Immunother (2012) 0.88
Aging affects the proportions of T and B cells in a group of elderly men in a developing country--a pilot study from Pakistan. Age (Dordr) (2012) 0.88
Relationships between cancer and aging: a multilevel approach. Biogerontology (2009) 0.88
Immune therapy for age-related diseases. Trends Immunol (2009) 0.88
Basic biology and clinical impact of immunosenescence. Exp Gerontol (2002) 0.88
Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis. J Rheumatol (2005) 0.87
Flow cytometric lymphocyte subset analysis using material from frozen whole blood. J Immunoassay Immunochem (2012) 0.86
Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol Immunother (2007) 0.85
Nutritional status influences peripheral immune cell phenotypes in healthy men in rural Pakistan. Immun Ageing (2012) 0.85
Impact of aging on cancer immunity and immunotherapy. Cancer Immunol Immunother (2009) 0.85
Impact of age, sex and CMV-infection on peripheral T cell phenotypes: results from the Berlin BASE-II Study. Biogerontology (2015) 0.84